Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Related Posts
How Funding Cuts Are Undermining Patient Recruitment in Clinical Trials
In a recent video interview with Applied Clinical Trials, Kyle McAllister, co-founder, CEO, Trially, discussed the impact of funding cuts…
Boehringer Announces Start of Phase II Geographic Atrophy Trial of Potential First-in-Class Therapy
Image Credit: © Pixel-Shot – stock.adobe.com Boehringer Ingelheim has announced the start of the JADE Phase II clinical trial (NCT06769048),…
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Credit: RAJCREATIONZS | stock.adobe.com Results from an ongoing Phase I trial have shown the potential of once-yearly intramuscular administration of…